505(b)(2) NDA Labeling
- Posted by: Ken Phelps
- Published on: January 15, 2009
All NDA submissions require that a draft label be included. For a 505(b)(2) NDA, where do you get the information for this label? What labeling is required?
What is labeling? Well, the “label” is what is on the immediate container of the drug product and can contain printed or graphic information. “Labeling” is all other labels (carton, etc.) and any other written, printed or graphic matter accompanying the drug product, including advertisements, brochures, etc. A very nice overview of Labeling is contained in this 2006 FDA presentation.
However, most people think of labeling as the package insert, containing information needed by the professional and the patient.
The Reference Listed Drug (RLD) labeling is always the starting point for the labeling of a new drug seeking approval through the 505(b)(2) process. Sections for the new drug labeling will differ from the RLD based on several factors. Generally, information from studies conducted by the new drug’s Sponsor is added. This may include additions or replacements to sections for PK/PD, efficacy, and/or safety.
Interestingly, even though the RLD may not currently have a patient information leaflet (PIL), FDA may require one for your product. PIL is a recent requirement for labeling that contains non-technical language so that a patient can understand the use of the medication. According to Part 208 – Medication Guides for Prescription Drug Products Sec. 208.1 (b) “The purpose of patient labeling for human prescription drug products required under this part is to provide information when the FDA determines in writing that it is necessary to patients’ safe and effective use of drug products.” This determination can be a topic of discussion with the FDA during the NDA review process.